Elise's star drug failed to go global

Economic Observer Follow 2026-10-07 16:46

Economic Observer reporter Zhang Ying

On October 6, 2026, Elise (688578. SH) announced on its official website that a global phase III clinical trial of its core product, Fumatinib, did not meet the primary endpoint and did not demonstrate a significant advantage in progression free survival (PFS) compared to chemotherapy.

Fumatinib is a star drug for the treatment of lung cancer, which was approved for market in China in March 2021. In the 2025 domestic innovative drug sales list in the Chinese market, Fumatinib ranks second. In the first half of 2026, its sales exceeded 3.1 billion yuan, a year-on-year increase of 33%. The sales of Fumatinib account for approximately 95% of Elys's total revenue in the first half of 2026.

At present, all sales of Fumatinib come from the Chinese market, and whether it can be launched overseas in the future depends on the progress of overseas clinical trials. The failure of the aforementioned clinical trials cast a shadow over its success.

In June 2021, three months after the approval of Fumatinib in China, Elise announced that it had built a bridge for the drug to enter overseas markets. At that time, Elise reached a cooperation agreement with American company ArriVent (AVBP. US) for the overseas development and commercialization of Fumetinib. Elise received a down payment of $40 million, cumulative R&D and sales milestone payments not exceeding $765 million, as well as sales commission fees and a certain percentage of ArriVent's shares.

This is an early attempt by Chinese pharmaceutical companies to explore the NewCo model in their overseas expansion. The establishment of ArriVent is closely related to famotinib. In April 2021, ArriVent was established. Two months later, ArriVent introduced Fumetinib and announced the completion of a $150 million Series A financing on the same day, with investors including Hillhouse Capital, Sequoia China, and Eli Lilly Asia Fund. Fumetinib was ArriVent's only drug asset at the time.

Bing Yao, Chairman and CEO of ArriVent, said that the company's strategy is to focus on identifying drug molecules like famotinib that have been validated through development processes in China and other regions, in order to help these drugs enter the United States, European Union, and other regions.

The global Phase III clinical trial announced on October 6th is the most advanced trial in the collaboration between Elise and ArriVent, covering 396 patients from the United States, Europe, Japan, China, and other regions. The aim of this trial is to investigate the efficacy and safety of famotinib compared to chemotherapy in first-line treatment of locally advanced or metastatic non squamous non-small cell lung cancer patients with EGFR 20 exon insertion mutations. EGFR exon 20 insertion mutations account for approximately 4% -12% of all EGFR mutations.

Frontline treatment refers to the initial treatment plan recommended by guidelines for patients after diagnosis, which often has the best effect and minimal side effects. Compared with second-line treatment, third line treatment, etc., its corresponding patient population is larger. For example, second-line treatment is mainly used for patients who have failed first-line treatment.

The experimental results showed that the median PFS of the 160mg Fumatinib group was 8.4 months, the 240mg Fumatinib group was 11 months, and the chemotherapy group was 9.5 months. Although the PFS of the 240mg Fumatinib patient group was longer than that of the chemotherapy group, it did not reach the predetermined statistical significance (P value of 0.0654).

It is worth noting that fumatinib is used as a second-line treatment for locally advanced or metastatic non squamous non-small cell lung cancer with EGFR 20 exon insertion mutations. Clinical trials have been conducted in China and it was approved for marketing by the China Food and Drug Administration in February 2026. The results of the first-line treatment trial announced this time indicate that the attempt to push Fumatinib from second-line treatment to first-line treatment for this disease has failed.

On October 6th, ArriVent also announced the results of the clinical trial, causing its stock price to drop by 47%.

However, the failure of this experiment does not mean that there is no hope for Fumatinib to go abroad. In addition to this trial, Elis and ArriVent are also collaborating on a global phase III clinical trial for first-line treatment of PACC mutant non-small cell lung cancer patients, as well as a global phase Ib trial for non-small cell lung cancer patients with EGFR or HER2 activating mutations.

Director of the Health News Department
Marquez once said that being a journalist is the best profession in the world.
WeChat: zhangy_1919
Email: zhangying@eeo.